[
  {
    "ts": null,
    "headline": "Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?",
    "summary": "Regeneron unveiled what it calls \"paradigm-shifting\" test results for a drug that could prevent patients from developing multiple myeloma.",
    "url": "https://finnhub.io/api/news?id=dcf977a2bc6e2599d37a000455caf112778cb173385a46670d73969b3b8ad19f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758305734,
      "headline": "Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?",
      "id": 136820664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron unveiled what it calls \"paradigm-shifting\" test results for a drug that could prevent patients from developing multiple myeloma.",
      "url": "https://finnhub.io/api/news?id=dcf977a2bc6e2599d37a000455caf112778cb173385a46670d73969b3b8ad19f"
    }
  },
  {
    "ts": null,
    "headline": "NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up",
    "summary": "Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.",
    "url": "https://finnhub.io/api/news?id=e70dfe42ab5dbe42e8c0c2c781b7b552d6cdd4e8e85416636fcc80f9a07075ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758302640,
      "headline": "NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up",
      "id": 136820740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.",
      "url": "https://finnhub.io/api/news?id=e70dfe42ab5dbe42e8c0c2c781b7b552d6cdd4e8e85416636fcc80f9a07075ea"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f9618a340d65c1b21af46792b7fc97f4c95cb14d2a3cbfd7333da07a46f2046d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758300360,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "id": 136872927,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f9618a340d65c1b21af46792b7fc97f4c95cb14d2a3cbfd7333da07a46f2046d"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas reboots, cuts more staff; Porges joins Lazard",
    "summary": "Pfizer and Arvinas plan to out-license their partnered drug vepdegestrant. Elsewhere, Novo shared more data for oral Wegovy and Vertex reached a deal in Italy for coverage of its gene editing medicine Casgevy.",
    "url": "https://finnhub.io/api/news?id=2a1cb1449022cead7cf7fe93a8d58116b1e362f699d68ca7725285eae9a45abe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758283560,
      "headline": "Arvinas reboots, cuts more staff; Porges joins Lazard",
      "id": 136820040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Pfizer and Arvinas plan to out-license their partnered drug vepdegestrant. Elsewhere, Novo shared more data for oral Wegovy and Vertex reached a deal in Italy for coverage of its gene editing medicine Casgevy.",
      "url": "https://finnhub.io/api/news?id=2a1cb1449022cead7cf7fe93a8d58116b1e362f699d68ca7725285eae9a45abe"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks",
    "summary": "Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense, also known as Zaire ebolavirus Supply is being rushed to Democratic Republic of Congo (DRC) to help with the current outbreak TARRYTOWN, N.Y., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will donate up to 500 doses of Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn",
    "url": "https://finnhub.io/api/news?id=3d18e706918bcc6c25ce1df1edf6dc8e3ff1403436ae771bc435507c259a7ac8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758283200,
      "headline": "Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks",
      "id": 136818583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense, also known as Zaire ebolavirus Supply is being rushed to Democratic Republic of Congo (DRC) to help with the current outbreak TARRYTOWN, N.Y., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will donate up to 500 doses of Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn",
      "url": "https://finnhub.io/api/news?id=3d18e706918bcc6c25ce1df1edf6dc8e3ff1403436ae771bc435507c259a7ac8"
    }
  }
]